China Healthcare Weekly (Aug.18)- COVID Is Here, BIOSECURE Act Update, Livzon Deserves More Patience
COVID is coming again. So investors can focus on related stocks. US companies leaving Chinese partners due to BIOSECURE Act. Livzon is still worth...
431 Views
Asia Ex-Japan:Â Extreme Stocks
We screen for stocks at the extreme ends of their positioning or momentum ranges. We combine current and historical data with recent manager...
386 Views
Sai Life Sciences Pre-IPO Tearsheet
SAI Life Sciences(SLS) is looking to raise up to US$500m in its upcoming India IPO. The deal will be run by Kotak, IIFL, Jefferies and MS.
427 Views
Pre-IPO Elpiscience Biopharmaceuticals - Will Investors Still Buy in These Stories?
​Elpiscience's strong capital operation capabilities are no longer enough as investors shift focus to cash flow and drug sales revenue. We have...
468 Views
Emcure Pharma Pre-IPO Trading - Strong Subscription, Will Pop
Emcure Pharmaceuticals raised around US$240m in its India IPO. Subscription rates were strong for institutional and HNI tranche.
357 Views